The test was approved by the FDA for adults aged 45 and older who are at average risk of cancer.
It works because large polyps, which can turn into cancer, shed DNA fragments that can be detected in the blood, The New York Times reported.
The company said it is the first blood test that the FDA has approved to be a primary screening for colorectal cancer. It is also the first that will meet Medicare requirements.
The test found 83% of colorectal cancers while a stool test called Cologuard had a 92.3% sensitivity rate, Reuters reported.
But Shield, according to The New York Times , can find colorectal cancer when it is at an early stage and curable. However, it does not find precancerous growths like a colonoscopy can.
Typically people have colonoscopies performed but the test is considered by some as inconvenient, Reuters reported. The blood test only found 13% of large polyps compared to 95% with a colonoscopy.
The American Cancer Society said the testing recommendation currently is fecal tests every three years and a colonoscopy every 10 years.
Still, it is hoped that more people will undergo the blood test and be screened, the Times reported.
The blood test is not new. It has been around since 2022 in the U.S. but was only a self-pay option, costing $895 and not covered by Medicare, according to Reuters .
It is estimated that as many as 53,000 Americans will die from colorectal cancer, according to the American Cancer Society .
Get updates delivered to you daily. Free and customizable.
Welcome to NewsBreak, an open platform where diverse perspectives converge. Most of our content comes from established publications and journalists, as well as from our extensive network of tens of thousands of creators who contribute to our platform. We empower individuals to share insightful viewpoints through short posts and comments. It’s essential to note our commitment to transparency: our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. We strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation. Join us in shaping the news narrative together.
Comments / 0